GRm13Z40-2 T-cell therapy

GRm13Z40-2 allogeneic CD8+ cytolytic T-cell line expressing IL-13-Zetakine and HyTK; glucocorticoid resistant · City of Hope Medical Center

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GRm13Z40-2 T-cell therapy, covering 2015-06-08 to 2015-06-08. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 [Phase 1]

See pricing